Sutro Biopharma, Inc. (STRO)
Market Cap | 272.43M |
Revenue (ttm) | 69.79M |
Net Income (ttm) | -122.74M |
Shares Out | 57.48M |
EPS (ttm) | -2.59 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 393,573 |
Open | 4.78 |
Previous Close | 4.73 |
Day's Range | 4.51 - 4.78 |
52-Week Range | 3.33 - 9.16 |
Beta | 0.92 |
Analysts | Buy |
Price Target | 22.57 (+376.16%) |
Earnings Date | Mar 27, 2023 |
About STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate rec... [Read more]
Financial Performance
In 2021, STRO's revenue was $61.88 million, an increase of 44.84% compared to the previous year's $42.72 million. Losses were -$105.54 million, 228.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for STRO stock is "Buy." The 12-month stock price forecast is $22.57, which is an increase of 376.16% from the latest price.
News

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and media...

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET -

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
- New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of Vaxcyte's Vaccine Candidates -

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which seven patients were MRD negative -

Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...

How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%
The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questiona...

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
- STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at ASH 2022 -

Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
--Results from compassionate use program highlight promising activity of STRO-002 in children with rare form of acute myeloid leukemia, that is highly refractory to all standard-of-care therapies-- --...

Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sutro Biopharma Announces Departure of Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...

Wall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 326% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionabl...

Does Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 293.4% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questiona...

Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 288%
The average of price targets set by Wall Street analysts indicates a potential upside of 288.1% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questiona...

Wall Street Analysts Think Sutro Biopharma, Inc. (STRO) Could Surge 295%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questiona...

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
- Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million in potential milestones per product candidate...

Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...

Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-for...

Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-for...